Lexeo Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $0.7 | — |
| Operating income | -$109.3 | -$105.8 | -$68.5 | -$60.5 | — |
| Net income | -$100.0 | -$98.3 | -$66.4 | -$59.3 | — |
| Cash Flow Statement | |||||
| Free cash flow | -$99.0 | -$81.6 | -$59.6 | -$55.2 | — |
| Share repurchases | — | $<0.1 | — | — | — |
Shares outstanding 82.0M · Free float 99.0%
Annual filing data through FY ended December 31, 2025; float as of October 6, 2026.